免疫检查点阻断疗法改变了癌症治疗的范式，此研究中通过美迪西在23 个同源肿瘤模型中进行了抗PD-1抗体的体内研究

Immune checkpoint blockade therapies have changed the paradigm of cancer therapies. Reseachers performed in vivo screening for anti-PD-1 therapy across 23 syngeneic tumor models and found that CT-26 and Colon 26, which are murine colorectal carcinoma derived from BALB/c mice, showed different sensitivity to anti-PD-1. In vivo studies for anti-PD-1 antibody across 23 syngeneic tumor models were performed by Medicilon.

Reference:

Yosuke Sato, et al. Tumor-immune profiling of CT-26 and Colon 26 syngeneic mouse models reveals mechanism of anti-PD-1 response. BMC Cancer. 2021 Nov 13;21(1):1222. doi: 10.1186/s12885-021-08974-3.